Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3696-3702

  Marsden, Matthew D ^a   Avancena, Patricia ^a   Kitchen, Christina M R ^b   Hubbard, Trish ^a   Zack, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; MK 2048; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; GENE MUTATION; HUMAN; HUMAN CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL;

BENZOXAZINES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MACROPHAGES; MUTATION; PYRROLIDINONES; ZIDOVUDINE;

EID: 79960319717     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00566-11     Document Type: Article

References (49)

1. Aquaro, S., et al. 2002. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 68:479-488.
2. Aquaro, S., et al. 1997. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J. Leukoc. Biol. 62:138-143.
3. Aquaro, S., et al. 2006. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J. Leukoc. Biol. 80:1103-1110.
4. Bacheler, L., et al. 2001. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 75:4999-5008. (Pubitemid 32448520)
5. Bar-Magen, T., et al. 2010. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84:9210-9216.
6. Brooks, D. G., S. G. Kitchen, C. M. Kitchen, D. D. Scripture-Adams, and J. A. Zack. 2001. Generation of HIV latency during thymopoiesis. Nature medicine. 7:459-464.
7. Burke, B., et al. 2007. Primary cell model for activation-inducible human immunodeficiency virus. J. Virol. 81:7424-7434. (Pubitemid 47047831)
8. Capparelli, E. V., et al. 2005. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19:949-952. (Pubitemid 40834938)
9. Cooper, D. A., et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
10. Croteau, D., et al. 2010. Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob. Agents Chemother. 54:5156-5160.
11. Dalgleish, A. G., et al. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767. (Pubitemid 15195924)
12. Delelis, O., et al. 2009. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 37:1193-1201.
13. Diamond, T. L., et al. 2004. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279:51545-51553.
14. Ferns, R. B., et al. 2009. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. Aids 23:2159-2164.
15. Fransen, S., et al. 2009. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J. Virol. 83:11440-11446.
16. Gartner, S., P. Markovits, D. M. Markovitz, R. F. Betts, and M. Popovic. 1986. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 256:2365-2371. (Pubitemid 17174464)
17. Gartner, S., et al. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219.
18. Gendelman, H. E., et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441.
19. Goethals, O., et al. 2010. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 402:338-346.
20. González-Scarano, F., and J. Martin-Garcia. 2005. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5:69-81.
21. Grinsztejn, B., et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269. (Pubitemid 46553846)
22. Ho, D. D., et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
23. Igarashi, T., et al. 2001. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. U. S. A. 98:658-663.
24. Koenig, S., et al. 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233:1089-1093. (Pubitemid 16032241)
25. Koh, Y., H. Haim, and A. Engelman. 2011. Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity. Antimicrob. Agents Chemother. 55:42-49.
26. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
27. Letendre, S. L., E. V. Capparelli, R. J. Ellis, and J. A. McCutchan. 2000. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob. Agents Chemother. 44:2173-2175.
28. Malet, I., et al. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
29. Markowitz, M., et al. 2007. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133.
30. Marsden, M. D., and J. A. Zack. 2007. Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J. Virol. 81:6146-6150.
31. McDougal, J. S., et al. 1985. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. J. Immunol. 135:3151-3162.
32. McElrath, M. J., J. E. Pruett, and Z. A. Cohn. 1989. Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc. Natl. Acad. Sci. U. S. A. 86:675-679.
33. Métifiot, M., C. Marchand, K. Maddali, and Y. Pommier. 2010. Resistance to Integrase Inhibitors. Viruses 2:1347-1366.
34. Michelini, Z., et al. Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. J. Virol. Methods 168:272-276.
35. Moltó, J., et al. 2011. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob. Agents Chemother. 55:72-75.
36. Murray, J. M., et al. 2007. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21:2315-2321. (Pubitemid 350287458)
37. Orenstein, J. M., M. S. Meltzer, T. Phipps, and H. E. Gendelman. 1988. Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 62:2578-2586.
38. Perelson, A. S., et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191. (Pubitemid 27209434)
39. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
40. Perno, C. F., et al. 1998. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 178:413-422.
41. Perno, C. F., et al. 2006. Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res. 71:293-300. (Pubitemid 44223775)
42. Perno, C. F., et al. 1988. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′- dideoxynucleosides. J. Exp. Med. 168:1111-1125.
43. Quercia, R., E. Dam, D. Perez-Bercoff, and F. Clavel. 2009. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J. Virol. 83:10245-10249.
44. Sedaghat, A. R., J. B. Dinoso, L. Shen, C. O. Wilke, and R. F. Siliciano. 2008. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl. Acad. Sci. U. S. A. 105:4832-4837.
45. Swingler, S., et al. 1999. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat. Med. 5:997-1003.
46. Van Wesenbeeck, L., et al. 2011. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob. Agents Chemother. 55:321-325.
47. Wiley, C. A., R. D. Schrier, J. A. Nelson, P. W. Lampert, and M. B. Oldstone. 1986. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc. Natl. Acad. Sci. U. S. A. 83:7089-7093.
48. Yilmaz, A., et al. 2009. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 4:e6877.
49. Zack, J. A., et al. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222.